Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: interferon alfa-2b Clear all
Completed Phase 2 Interventional

PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

NCT00045279
View directory record Official record
Conditions
Kidney Cancer
Interventions
PEG-interferon alfa-2b
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 26, 2026, 2:10 AM EDT
Completed Phase 3 Interventional

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

NCT00004196
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
recombinant interferon alfa, lymphangiography, Observation
Biological · Procedure · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
4
States / cities
Birmingham, Alabama • Louisville, Kentucky • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Sep 26, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C

NCT00919633
View directory record Official record
Conditions
Hepatitis C
Interventions
interferon alfa-2b, peginterferon alfa-2b, ribavirin, USP, external drug infusion pump
Drug · Device
Lead sponsor
Medtronic Corporate Technologies and New Ventures
Industry
Eligibility
18 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 26, 2026, 2:10 AM EDT
Not listed Phase 4 Interventional

A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)

NCT01731301
View directory record Official record
Conditions
Chronic Hepatitis C, End Stage Renal Disease
Interventions
Ribavirin, Peginterferon, Boceprevir
Drug
Lead sponsor
Liver Institute of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2012 · Synced Sep 26, 2026, 2:10 AM EDT
Completed Not applicable Interventional

CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma

NCT00574730
View directory record Official record
Conditions
Non-Hodgkins Lymphoma
Interventions
CHOP/Rituximab, PEG INTRON
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Sep 26, 2026, 2:10 AM EDT
Terminated Phase 1 Interventional

Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma

NCT00311558
View directory record Official record
Conditions
Cancer
Interventions
recombinant interferon alfa-2b, sodium stibogluconate, SSG & interferon
Biological · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Sep 26, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation

NCT00548847
View directory record Official record
Conditions
Leukemia
Interventions
GM-CSF, Interferon-α-2b
Biological
Lead sponsor
Emory University
Other
Eligibility
1 Year and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 26, 2026, 2:10 AM EDT
Completed Phase 1Phase 2 Interventional

Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer

NCT00030342
View directory record Official record
Conditions
Colorectal Cancer, Kidney Cancer
Interventions
recombinant interferon alfa, sargramostim, therapeutic autologous lymphocytes, fluorouracil
Biological · Drug
Lead sponsor
St. Luke's Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 26, 2026, 2:10 AM EDT
Terminated Phase 2 Interventional

Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

NCT00098618
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
sorafenib tosylate, recombinant interferon alfa, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 26, 2026, 2:10 AM EDT
Recruiting Phase 3 Interventional

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06510374
View directory record Official record
Conditions
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Interventions
Nadofaragene Firadenovec
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
53
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 26, 2026, 2:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies

NCT02151448
View directory record Official record
Conditions
Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
Interventions
DC vaccine, Celecoxib, Interferon Alfa-2b, rintatolimod
Biological · Drug
Lead sponsor
David Bartlett
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Sep 26, 2026, 2:10 AM EDT
Terminated Phase 2 Interventional

Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00176527
View directory record Official record
Conditions
Prostate Cancer
Interventions
recombinant interferon alfa-2b, docetaxel, estramustine phosphate sodium, isotretinoin, polyacrylamide gel electrophoresis, protein expression analysis, immunohistochemistry staining method
Biological · Drug · Genetic + 1 more
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Sep 26, 2026, 2:10 AM EDT
Terminated Phase 1 Interventional

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

NCT00791271
View directory record Official record
Conditions
Melanoma
Interventions
Decitabine, Pegylated Interferon Alpha-2b
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Sep 26, 2026, 2:10 AM EDT
Completed Phase 2 Interventional

Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer

NCT00059826
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
interferon-alfa-2b, cisplatin, 5-fluorouracil, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
14
States / cities
Gainesville, Florida • Chicago, Illinois • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Sep 26, 2026, 2:10 AM EDT
Completed Phase 1 Interventional

An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals

NCT00489385
View directory record Official record
Conditions
HIV Infections, HCV
Interventions
Albinterferon, Ribavirin, Albuferon
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 26, 2026, 2:10 AM EDT
Terminated Phase 2 Interventional

Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia

NCT00005984
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, filgrastim, recombinant interferon alfa, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 26, 2026, 2:10 AM EDT
Completed No phase listed Observational Results available

A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma

NCT01986712
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
St. Luke's Hospital and Health Network, Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
4
States / cities
Tampa, Florida • Buffalo, New York • Bethlehem, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 26, 2026, 2:10 AM EDT
Terminated Phase 1 Interventional Results available

PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00589550
View directory record Official record
Conditions
Kidney Cancer
Interventions
PEG-interferon alfa-2b, Sorafenib, gene expression analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
Thomas Olencki
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 26, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas

NCT02343224
View directory record Official record
Conditions
Juvenile Pilocytic Astrocytomas, Optic Pathway Gliomas
Interventions
Pegylated interferon alpha-2b
Drug
Lead sponsor
Emory University
Other
Eligibility
3 Years to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Sep 26, 2026, 2:10 AM EDT
Terminated Phase 1Phase 2 Interventional

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

NCT00085384
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
PEG-interferon alfa-2b, PEG-interferon alfa-2b
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Sep 26, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

NCT01482767
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 26, 2026, 2:10 AM EDT
Completed Phase 2 Interventional

Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer

NCT00445523
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
TroVax® (Immunological Vaccine Therapy), Interferon-alpha
Biological · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 26, 2026, 2:10 AM EDT
Completed Phase 1 Interventional

Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma

NCT00970996
View directory record Official record
Conditions
Melanoma
Interventions
Temozolomide, Abraxane, Cisplatin, Interleukin-2, Interferon alpha 2b
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Sep 26, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

NCT03710876
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
rAd-IFN, Celecoxib Oral Product, Gemcitabine
Biological · Drug
Lead sponsor
Ferring Ventures Limited
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 26, 2026, 2:10 AM EDT